Fractyl expands ERASE Task Force to study underlying GLP-1-based pancreatic gene therapy for T2DMFractyl Health has expanded an academic-industry scientific partnership charged with advancing research on the role of the gut and...
Carmot begins Phase 2 trial of dual GLP-1/GIP RA CT-868 for the treatment of type 1 diabetesCarmot Therapeutics has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult...
People with obesity burn less energy during dayA study by researcher at Oregon Health & Science University has found people who have a healthy weight use more energy during the day,...
Journal Watch 15/11/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Updates on banded procedure studies and randomised controlled trialsAt the recent International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress in Naples, Italy,...
SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesitySemaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment2 days ago